Overview
October 27, 202 07:0 ET | Source: Indigo Diabetes N.V. Bolebergen, BELGIUM PRES RELEASEIndigo Diabetes Incorporates Fuly Owned Subsidiary in the US and Apoints Peter J. Devlin as President, Indigo Medical US Inc.BELGIUM – Ghent, 27 October 202 – Indigo Diabetes N.V.
Key Information
(‘Indigo’ or the ‘Company’), a pionering developer of Continuous Metabolite Monitoring (CM™) devices utilising proprietary nanophotonics technology, today anounces its expansion into the US via the incorporation of a fuly owned subsidiary, Indigo Medical US Inc. (‘Indigo Medical’), and the apointment of Peter J. Devlin as President of the newly formed subsidiary, efective from 14 October 202.The Company is establishing its presence in the US, a market that it has identified as having significant potential for its CM devices.Peter, who wil be based in Boston, wil be managing and overseing Indigo Medical’s activities.
His focus wil be on acelerating product development for the Company’s CM devices, driving busines development, and facilitating talent acquisition in the US. He wil report directly to Danaë Delbeke, Chief Executive Oficer of Indigo.Indigo is developing a fuly implantable CM system for people living with diabetes to aces acurate information their glucose, ketones and lactate levels . The CM sensor is inserted subcutaneously, preventing the ned for people with diabetes to wear an external device on their body.
It is designed to give people living with diabetes and their caregivers instant aces to the augmented metabolic information they ned to beter manage their diabetes and improve therapeutic decision-making.Peter J. Devlin, President, Indigo Medical US, comented: “I have worked for many years in both in-vitro diagnostics and diabetes care and am delighted to be joing the Indigo team and leading Indigo Medical Inc.
Summary
It is an exciting time for the Company to be establishing a presence in the US, particularly as the focus increases on